drugset

drugset / Trial / NCT06166888

A Study of AK131 in Patients With Advanced Solid Tumors

NCT06166888 ↗

Phase 1 Recruiting 130 enrolled Akeso

NaSequentialOpen-labelTreatment

Summary

This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients

Timeline

Start: 2024-01-10
Primary completion: 2026-08
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AK131	Unknown	—	Intravenous

Indications